Partnering Agreements in Diagnostics

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Overview of diagnostic dealmaking

• 2.1. Introduction
• 2.2. The anatomy of diagnostic partnering
  • 2.2.1. The anatomy of an oncology deal
  • 2.2.1.a. Case study 1: Sequenom - Lenetex - January 2007
  • 2.2.1.b. Case study 2: Celera - Siemens Medical Solutions - July 2007
  • 2.2.1.c. Case study 3: US Genomics - Rosetta Genomics - May 2006
• 2.3. Litigation and settlement in diagnostics

Chapter 3 - Trends in diagnostic dealmaking

• 3.1. Introduction
• 3.2. Diagnostic partnering over the years
• 3.3. Most active diagnostic dealmakers
• 3.4. Bigpharma diagnostic dealmaking activity
• 3.5. Bigpharma not active in diagnostics
• 3.6. Oncology partnering by deal type
• 3.7. Diagnostic M&A activity since 2000

Chapter 4 - Leading diagnostic deals

• 4.1. Introduction
• 4.2. Top diagnostic deals by value
• 4.3. Top diagnostic involving bigpharma
• 4.4. Leading diagnostic M&A deals by value

Chapter 5 - Bigpharma diagnostic deals

• 5.1. Introduction
• 5.2. How to use bigpharma diagnostic partnering deals
• 5.3. Bigpharma partnering company profiles
  • Abbott
  • Actavis
  • Alcon Labs
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cephalon
  • Chugai
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • Johnson & Johnson
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck - Serono
  • Mitsubishi Tanabe
  • Mylan
  • Novartis
  • Novo Nordisk
  • Nycomed Pharma
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Ratiopharm
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Servier
  • Shire
  • Solvay
  • Takeda
  • Teva
  • UCB
  • Watson
  • Wyeth

Chapter 6 - Diagnostic dealmaking directory

• 6.1. Introduction
• 6.2. Company A-Z
• 6.3. By stage of development
  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed
• 6.4. By deal type
  • Asset and product purchase
  • Collaborative R&D
  • Co-development
  • Co-marketing
  • Co-promotion
  • Development
  • Distribution
  • Joint venture
  • Licensing
  • M&A
  • Manufacturing
  • Marketing
  • Promotion
  • Option
  • Research
  • Supply
• 6.5. By therapy area
  • Cardiovascular
  • Central nervous system
  • Dermatology
  • Gastrointestinal
  • Genitourinary
  • Hematology
  • Immunology
  • Infection
  • Inflammation
  • Metabolic
  • Musculoskeletal
  • Oncology
  • Ophthalmics
  • Respiratory
  • Animal health

Chapter 7 - Diagnostic partnering resource center

• 7.1. Online diagnostic partnering
• 7.2. Diagnostic partnering events
• 7.3. Further reading on diagnostic dealmaking

Appendices

• Appendix 1 - Deal type definitions
• Appendix 2 - Example diagnostic partnering agreement
• About CurrentPartnering
• Recent titles from CurrentPartnering

Figures in report

• Figure 1: Components of the typical diagnostic deal structure
• Figure 2: Settlement licensing agreements since 2003
• Figure 3: Diagnostic partnering since 2000
• Figure 4: Most active diagnostic dealmakers 2003-2008
• Figure 5: Bigpharma - top 50 - diagnostic deals 2003 to 2008
• Figure 6: Inactive bigpharma in diagnostic dealmaking 2003-2008
• Figure 7: Diagnostic partnering by deal type since 2003
• Figure 8: Diagnostic option deals since 2003
• Figure 9: Diagnostic partnering by disease type from 2003
• Figure 10: Diagnostic M&A since 2000
• Figure 11: Top diagnostic deals by value since 2000
• Figure 12: Top diagnostic deals signed by bigpharma value since 2000
• Figure 13: Top diagnostic M&A deals by value since 2000
• Figure 14: Online partnering resources
• Figure 15: Forthcoming partnering events
• Figure 16: Deal type definitions
• Figure 17: Diagnostics partnering agreement between Inhibitex and 3M, February 2007